Enrolling by invitationPhase 3NCT06044337

A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Studying Chronic cutaneous lupus erythematosus

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Biogen
Principal Investigator
Medical Director
Biogen
Intervention
BIIB059 (litifilimab)(drug)
Enrollment
322 enrolled
Eligibility
18 years · All sexes
Timeline
20232029

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06044337 on ClinicalTrials.gov

Other trials for Chronic cutaneous lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Chronic cutaneous lupus erythematosus

← Back to all trials